Pleased to announce FDA approval of YARTEMLEA® (narsoplimab-wuug). First and only approved lectin pathway inhibitor therapy indicated for TA-TMA.
More info: bit.ly/497VHeF
#YARTEMLEA #narsoplimab #ComplementInhibition #RareDisease #TMAtreatment #NowApproved #MASP2inhibitor #tma #hsct #omeros #FDA
More info: bit.ly/497VHeF
#YARTEMLEA #narsoplimab #ComplementInhibition #RareDisease #TMAtreatment #NowApproved #MASP2inhibitor #tma #hsct #omeros #FDA
December 24, 2025 at 2:53 PM
Pleased to announce FDA approval of YARTEMLEA® (narsoplimab-wuug). First and only approved lectin pathway inhibitor therapy indicated for TA-TMA.
More info: bit.ly/497VHeF
#YARTEMLEA #narsoplimab #ComplementInhibition #RareDisease #TMAtreatment #NowApproved #MASP2inhibitor #tma #hsct #omeros #FDA
More info: bit.ly/497VHeF
#YARTEMLEA #narsoplimab #ComplementInhibition #RareDisease #TMAtreatment #NowApproved #MASP2inhibitor #tma #hsct #omeros #FDA
#NovoNordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor #zaltenibart with best-in-class potential across multiple therapeutic areas of #complement-driven disorders. Deal valued up to $2.1B plus tiered royalties. Learn more: bit.ly/47r7wg8
October 15, 2025 at 12:41 PM
#NovoNordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor #zaltenibart with best-in-class potential across multiple therapeutic areas of #complement-driven disorders. Deal valued up to $2.1B plus tiered royalties. Learn more: bit.ly/47r7wg8
Omeros announces robust improvement in survival for #narsoplimab expanded access program in #TA-TMA over external control. More info: shorturl.at/NA9fy #complementinhibitor #omeros
Omeros Corporation - Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
The Investor Relations website contains information about Omeros Corporation's business for stockholders, potential investors, and financial analysts.
shorturl.at
February 20, 2025 at 7:47 PM
Omeros announces robust improvement in survival for #narsoplimab expanded access program in #TA-TMA over external control. More info: shorturl.at/NA9fy #complementinhibitor #omeros
Omeros announced 2 presentations that will be featured at the 2025 Tandem Meetings – Feb 12-15, 2025 in Honolulu, HI. Both presentations report real world outcomes from patients with TA-TMA treated with narsoplimab supplied by Omeros under an expanded access program. shorturl.at/D2nrP #Tandem25
Omeros Corporation - Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
The Investor Relations website contains information about Omeros Corporation's business for stockholders, potential investors, and financial analysts.
shorturl.at
February 10, 2025 at 7:26 PM
Omeros announced 2 presentations that will be featured at the 2025 Tandem Meetings – Feb 12-15, 2025 in Honolulu, HI. Both presentations report real world outcomes from patients with TA-TMA treated with narsoplimab supplied by Omeros under an expanded access program. shorturl.at/D2nrP #Tandem25
Omeros announces newly completed sensitivity analyses demonstrating robustness of previously announced survival superiority over external control in #TA-#TMA More info: investor.omeros.com/news-release... #narsoplimab #complementinhibitor #omeros
Omeros Corporation - Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
The Investor Relations website contains information about Omeros Corporation's business for stockholders, potential investors, and financial analysts.
investor.omeros.com
January 17, 2025 at 12:35 AM
Omeros announces newly completed sensitivity analyses demonstrating robustness of previously announced survival superiority over external control in #TA-#TMA More info: investor.omeros.com/news-release... #narsoplimab #complementinhibitor #omeros